Analysis10k / Blog
EN한국어ES
Reverse DCF · UNH

What UNH's Stock Price Is Really Betting On

The short answer

At today's price, UnitedHealth's stock is pricing in about 5.6% annual free-cash-flow growth for the next ten years. Before its 2025 crisis, the company's actual free-cash-flow growth ran 13.6% a year — but including the crisis, the trailing five-year rate was actually -5.2% a year.

The conclusion

At its current price, UNH implies ~5.6% annual free-cash-flow growth for the next 10 years, discounted at 10%.

Pre-crisis (2021–2023), UnitedHealth's actual FCF growth averaged 13.6% a year. Including the 2025 crisis, the trailing five-year (2021–2025) rate was -5.2% a year.

Verdict: the market expects a partial, not full, recovery This price doesn't require UnitedHealth to return to its 2021–2023 growth pace (13.6%) — only a modest 5.6% annual climb. But it does assume the 2025 crisis doesn't repeat. Whether that assumption holds is exactly the question worth digging into next.

5.6% needed vs. 13.6% growth before the crisis, but -5.2% including it

Market's ask (WACC 10%)
5.6%
Pre-crisis FCF growth (2021→23)
13.6%
5-yr FCF growth (2021→25, incl. crisis)
-5.2%
5-yr revenue growth (2021→25)
11.7%

Required growth from the reverse DCF below. FCF = operating cash flow − capital expenditures. Pre-crisis CAGR: 2021 FCF ($19,889M) to 2023 peak ($25,682M). Five-year CAGR: 2021 FCF ($19,889M) to 2025 ($16,075M). Revenue CAGR: 2021 ($287,597M) to 2025 ($447,567M). Source: 10-K FY2025, p.27, p.44; 10-K FY2021, p.27, p.43.

From 1.4% to 9.2%: the discount-rate range

Required growth by discount rate: 8% gives 1.4%, 9% gives 3.6%, 10% gives 5.6%, 12% gives 9.2%1.4%8%3.6%9%5.6%10% (base)9.2%12%
Discount rate (bottom) vs. the growth the price then requires.
Required 10-year FCF growth by discount rate (WACC)
WACCRequired growth
8%1.4%
9%3.6%
10% (base case)5.6%
12%9.2%

UnitedHealth is classified as a large, stable company (market cap over $350B), giving it a base-case WACC of 10%. At a lower discount rate (8%), required growth falls to just 1.4%; at a higher one (12%), it climbs to 9.2% — nearly double the base case.

What would change UnitedHealth's 5.6%

  • Switching the FCF base from trailing-twelve-month ($23,617M) to the FY2025 audited figure alone ($16,075M) raises the required growth rate sharply, from 5.6% to 10.8% — because 2025 was the crisis trough, using it as the starting point demands a much steeper future climb.
  • Using a three-year (2023–2025) average FCF ($20,821M) instead puts the required growth rate at 7.3%, in between.
  • Lowering the terminal growth rate from 2.5% to 2.0% raises the required growth rate slightly, since a smaller terminal value has to be made up for during the explicit growth period.

The math behind 5.6%

Inputs, sources, model assumptions, and the calculation
  • Share price$395.62 — stockanalysis.com, Aug 17, 2026 close
  • Diluted shares outstanding906M — 10-Q Q2 FY2026, income statement (three months ended Jun 30, 2026)
  • Market cap$358,432M — price × diluted shares (calculated)
  • Net debt$44,743M — 10-Q Q2 FY2026 balance sheet: total debt ($73,328M) minus cash and equivalents ($28,585M), as of Jun 30, 2026
  • Trailing-twelve-month FCF$23,617M — calculated: FY2025 FCF ($16,075M) minus H1 2025 FCF ($10,860M) plus H1 2026 FCF ($18,402M), from the 10-Q Q2 FY2026 cash flow statement
  • Discount rate (WACC)10% base case (8% / 12% tested) — large stable-company default
  • Terminal growth rate2.5% — long-run GDP-level assumption

Normalization check: trailing-twelve-month FCF ($23,617M) is +13.4% above the three-year (2023–2025) average ($20,821M) — within the ±40% threshold, so used as-is without adjustment. FY2025 alone, by contrast, sits -22.8% below that same three-year average, confirming 2025 was a genuine trough year.

Model: free cash flow is assumed to grow at a constant annual rate g for 10 years, then at a 2.5% terminal rate thereafter, solved by bisection for the value of g that equates present value to today's enterprise value (market cap + net debt).

Limits of the UNH number

This number is a starting point, not an answer
  • Change the discount rate, the FCF base, the projection window, or the terminal growth rate, and the answer moves significantly — see the sensitivity table above.
  • A reverse DCF shows what the market currently expects — it does not say what the stock is "worth."
  • Whether 5.6% growth is realistic depends on whether the 2025 crisis (guidance collapse, CEO change, DOJ investigation) is genuinely over — this math alone can't answer that.
  • Any investment decision, and its outcome, is your own responsibility.
Built from UnitedHealth Group's 10-K (FY2021, FY2025) and 10-Q (Q2 FY2026) filings, plus a web search for the current share price (stockanalysis.com, Aug 17, 2026). This tells you where to dig deeper — it is not a buy or sell signal.

What we'd watch next

These three checks would show whether this read is holding up. They are prompts for your own follow-up, not predictions.

  • Free cash flow recoveryThe price needs about 5.6% a year; the trailing five years were -5.2%. A real recovery must show up here.
  • Pre-crisis vs. trailing baseThe two bases point in opposite directions. Decide which better describes today.
  • Medicare rate outcomesReimbursement outcomes drive the next few years' margins.

How this number is built, and how banks, REITs, and negative cash flow are handled: see our methodology.

Frequently asked questions

What growth rate does UNH's stock price assume?

At today's price, UnitedHealth's stock is pricing in about 5.6% annual free-cash-flow growth for the next ten years.

How does that compare to UnitedHealth's actual growth?

Before its 2025 crisis, UnitedHealth's actual free-cash-flow growth ran 13.6% a year — well above what the price now requires — but including the crisis, the trailing five-year rate was actually -5.2% a year.

What share price was used for this analysis?

This analysis used $395.62, as of Aug 17, 2026.